title: Cross-resistance of imatinib mesylate and 17-AAG in imatinib-resistant cells that overexpress BCR-ABL.
authors.forename: Julian
authors.initials: J
authors.lastname: Topaly
authors.forename: Moritz
authors.initials: M
authors.lastname: Schad
authors.forename: Stephanie
authors.initials: S
authors.lastname: Laufs
authors.forename: Junia V
authors.initials: JV
authors.lastname: Melo
authors.forename: W Jens
authors.initials: WJ
authors.lastname: Zeller
authors.forename: Stefan
authors.initials: S
authors.lastname: Fruehauf
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D016227:Benzoquinones; D015153:Blotting, Western; D019008:Drug Resistance, Neoplasm; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism*; D006801:Humans; D000068877:Imatinib Mesylate; D020014:K562 Cells; D047029:Lactams, Macrocyclic; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D017828:Rifabutin / Q000031:analogs & derivatives* / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D016227:Benzoquinones; D004791:Enzyme Inhibitors; D047029:Lactams, Macrocyclic; D010879:Piperazines; D011743:Pyrimidines; D017828:Rifabutin; C112765:tanespimycin; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl